Comparison · NCT05001737-sae
Cohort 1 (sJIA and AOSD) vs Cohort 2 (SLE): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Cohort 1 (sJIA and AOSD) vs Cohort 2 (SLE): serious adverse events. Trial comparisons, record NCT05001737-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05001737-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.72 | 0.524 | 0.857 | wilson | |
| Risk in group 2 | 0.5 | 0.215 | 0.785 | wilson | |
| Risk difference, group 1 minus group 2 | 0.22 | -0.126 | 0.536 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.44 | 0.691 | 3 | log | |
| Odds ratio, group 1 over group 2 | 2.57 | 0.5 | 13.2 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Cohort 1 (sJIA and AOSD) than on Cohort 2 (SLE) | 4.55 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Cohort 1 (sJIA and AOSD) | MAS in the context of systemic juvenile idiopathic arthritis and adult onset Still's disease (sJIA and AOSD)~Emapalumab: Emapalumab iv infusion | 18 | 25 | EG000 |
| Group 2 | Cohort 2 (SLE) | MAS in the context of systemic lupus erythematosus (SLE)~Emapalumab: Emapalumab iv infusion | 4 | 8 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From signature of informed consent (i.e. screening) until EOS (1 year)
Source ClinicalTrials.gov
Trial
- Title
- Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
- NCT number
- NCT05001737
- Phases
- PHASE3
- Conditions
- Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus, SJIA, AOSD, MAS
- Interventions
- Emapalumab
- Lead sponsor
- Swedish Orphan Biovitrum
- Results first posted
- 2026-02-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05001737?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05001737-sae